Ajay Manhapra1, Lantie Quinones2, Robert Rosenheck3. 1. Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; VA New England Mental Illness Research and Education Center, West Haven, CT, United States; Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States. Electronic address: ajay.manhapra@yale.edu. 2. Department of Psychiatry, Harvard Medical School & McLean Hospital, Belmont, MA, United States. 3. VA New England Mental Illness Research and Education Center, West Haven, CT, United States; Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States.
Abstract
BACKGROUND: The advent of buprenorphine as an alternative to methadone has dramatically shifted the landscape of opioid agonist therapy (OAT) for opioid use disorder (OUD). However, there is limited US national level data describing thedifferences between patients who are prescribed these two OAT options. METHODS: From veterans with OUD diagnosis who used Veterans Health Administration services in 2012, we identified 3 mutually exclusive groups: those who received (1) buprenorphine only (n=5,670); (2) methadone only (n=6,252); or (3) both buprenorphine and methadone in the same year (n=2513). We calculated the bi-varate effect size differences (risk ratios and Cohen's d) forcharacteristics that differentiated these groups. Logistic regression analysis was then used to identify factors independently differentiating the groups. RESULTS: Ten year increment in age (OR 0.67; 95% CI 0.64-0.70), urban residence (OR 0.26; 95% CI 0.25-0.33), and black race (OR 0.39; 95% CI 0.35-0.43) were strongly and negatively associated with odds of receiving buprenorphine compared to methadone, while medical and psychiatric comorbidities or receipt of other psychiatric medications did not demonstrate substantial differences between groups. CONCLUSIONS: Differences between veterans receiving buprenorphine or methadone based OAT seems to be largely shaped by demographic characteristics rather than medical or psychiatric or service use characteristics. A clearer understanding of the reasons for racial differences could be helpful in assuring that black OUD patients are not denied the opportunity to receive buprenorphine if that is their preference. Published by Elsevier Ireland Ltd.
BACKGROUND: The advent of buprenorphine as an alternative to methadone has dramatically shifted the landscape of opioid agonist therapy (OAT) for opioid use disorder (OUD). However, there is limited US national level data describing thedifferences between patients who are prescribed these two OAT options. METHODS: From veterans with OUD diagnosis who used Veterans Health Administration services in 2012, we identified 3 mutually exclusive groups: those who received (1) buprenorphine only (n=5,670); (2) methadone only (n=6,252); or (3) both buprenorphine and methadone in the same year (n=2513). We calculated the bi-varate effect size differences (risk ratios and Cohen's d) forcharacteristics that differentiated these groups. Logistic regression analysis was then used to identify factors independently differentiating the groups. RESULTS: Ten year increment in age (OR 0.67; 95% CI 0.64-0.70), urban residence (OR 0.26; 95% CI 0.25-0.33), and black race (OR 0.39; 95% CI 0.35-0.43) were strongly and negatively associated with odds of receiving buprenorphine compared to methadone, while medical and psychiatric comorbidities or receipt of other psychiatric medications did not demonstrate substantial differences between groups. CONCLUSIONS: Differences between veterans receiving buprenorphine or methadone based OAT seems to be largely shaped by demographic characteristics rather than medical or psychiatric or service use characteristics. A clearer understanding of the reasons for racial differences could be helpful in assuring that black OUD patients are not denied the opportunity to receive buprenorphine if that is their preference. Published by Elsevier Ireland Ltd.
Entities:
Keywords:
Buprenorphine; Demographics; Methadone; Opioid agonist treatment; Opioid use disorder
Authors: Helena B Hansen; Carole E Siegel; Brady G Case; David N Bertollo; Danae DiRocco; Marc Galanter Journal: J Behav Health Serv Res Date: 2013-07 Impact factor: 1.505
Authors: Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm Journal: MMWR Morb Mortal Wkly Rep Date: 2015-07-10 Impact factor: 17.586
Authors: Jessica J Wyse; Adam J Gordon; Steven K Dobscha; Benjamin J Morasco; Elizabeth Tiffany; Karen Drexler; Friedhelm Sandbrink; Travis I Lovejoy Journal: Subst Abus Date: 2018 Impact factor: 3.716
Authors: Utibe R Essien; Florentina E Sileanu; Xinhua Zhao; Jane M Liebschutz; Carolyn T Thorpe; Chester B Good; Maria K Mor; Thomas R Radomski; Leslie R M Hausmann; Michael J Fine; Walid F Gellad Journal: J Gen Intern Med Date: 2020-01-21 Impact factor: 5.128
Authors: Gwen Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Abigail G Matthews; Jennifer McCormack; David Liu; Jeffrey H Samet; Andrew J Saxon; Cynthia I Campbell; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Ingrid A Binswanger; Bobbi Jo H Yarborough; Katharine A Bradley Journal: Drug Alcohol Depend Date: 2019-11-15 Impact factor: 4.492
Authors: Paul J Joudrey; Gavin Bart; Robert K Brooner; Lawrence Brown; Julie Dickson-Gomez; Adam Gordon; Sarah S Kawasaki; Jane M Liebschutz; Edward Nunes; Dennis McCarty; Robert P Schwartz; José Szapocnik; Madhukar Trivedi; Judith I Tsui; Arthur Williams; Li-Tzy Wu; David A Fiellin Journal: Subst Abus Date: 2021 Impact factor: 3.716
Authors: Jessica J Wyse; Jonathan L Robbins; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Julie R Gaither; Kirsha Gordon; Melissa Skanderson; Declan T Barry; Stephen Crystal; Amy Justice; Kevin L Kraemer Journal: Drug Alcohol Depend Date: 2019-03-09 Impact factor: 4.852
Authors: Judith I Tsui; Mary A Akosile; Gwen T Lapham; Denise M Boudreau; Eric A Johnson; Jennifer F Bobb; Ingrid A Binswanger; Bobbi Jo H Yarborough; Joseph E Glass; Rebecca C Rossom; Mark T Murphy; Chinazo O Cunningham; Julia H Arnsten; Manu Thakral; Andrew J Saxon; Joseph O Merrill; Jeffrey H Samet; Gavin B Bart; Cynthia I Campbell; Amy M Loree; Angela Silva; Angela L Stotts; Brian Ahmedani; Jordan M Braciszewski; Rulin C Hechter; Thomas F Northrup; Viviana E Horigian; Katharine A Bradley Journal: J Gen Intern Med Date: 2021-02-10 Impact factor: 5.128